We need more prospective bio marker studies, particularly to study the role of ct DNA MRD. Tic Tac Toe study is interesting !

#CTTI seeks an Engagement Specialist to shape strategies, drive engagement projects, and foster community initiatives. Sound like you? Apply now! bit.ly/4b5X1Oo

Drivers of Clinical Trial Participation -- Demographics, Disparities, and Eligibility Criteria [Jan 10, 2019] Mishkin, Arnaldez, Ivy JAMA Oncology ow.ly/okeU30o3vAc #ClinicalTrials SWOG Cancer Research Network #SWOGonc

We are continuously progressing in lung cancer therapy!

If you’re using the Computational Resources for #CancerResearch portal, then @DOE-nick wants your input! Discuss cancer computing needs and provide your feedback during this upcoming meeting. Email [email protected] to register and get more information.

Inspired effort by a few will have a big impact for many

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group [Feb 9, 2021] Allison Magnuson, DO, MS et al. ASCO Friends of Cancer Research Clinical Cancer Research ow.ly/H6qM50Dw8uD #ClinicalTrials #ctsm FDA Oncology

This morning opening of AACR - FDA workshop of treatment of early stage solid cancers. Honored to be a panelist !

Modernizing #ClinicalTrials I/E: Recs ASCO Friends of Cancer Research HIV Working Group [10/2/17] Uldrick et al. Journal of Clinical Oncology ow.ly/bAxJ30fDFkA #IDOnc

Modernizing #ClinicalTrials I/E: Recs ASCO Friends of Cancer Research Brain Metastases [10/2/17] Lin et al. Journal of Clinical Oncology ow.ly/NtXV30fDF21 #camets

Re-Evaluating I/E Criteria for Oncology #ClinicalTrials : Analysis of IND Apps in 2015 [10/2/17] Jin et al. Journal of Clinical Oncology ow.ly/HRqb30fDFI7

Modernizing #ClinicalTrials Eligibility: Recs ASCO Friends of Cancer Research Minimum Age Work Group [10/2/17] Gore et al. Journal of Clinical Oncology ow.ly/i5bl30fDDL9

Karen Knudsen Karen Knudsen, MBA PhD: 'As a leader, when you have a greater insight into the things that your people are thinking about as they’re trying to improve the lives of cancer patients and their families every day, you’re going to be better off.'
cancerletter.com/conversation-w…

Reevaluating Eligibility Criteria: Balancing Patient Protection & Participation [Apr 20, 2017] Beaver, Ison Rick Pazdur NEJM ow.ly/i65N30b0qac #ClinicalTrials

Here’s a funding opportunity allowing investigators to create a predoctoral training program in computational and #DataScience analytics to support #CancerResearch . datascience.cancer.gov/news-events/ne… NIH Funding @NIH

How Much is Enough? Trial Designs for Treatment Regimens with Multiple Phases:
AACR Past President Dr. Elizabeth Jaffee and Harpreet Singh will chair this AACR-U.S. FDA workshop. Join us online May 9. Learn more:
bit.ly/3JULR3I
#AACRSciencePolicy Harpreet Singh, MD

⚡️ On nature - Geographic variation of mutagenic exposures in kidney cancer genomes

#kidneyCancer

nature.com/articles/s4158…

Congratulations to Qingyu Luo and our amazing team and collaborators! Tweetorial with more details to come soon... nature.com/articles/s4158…

Dr. Richard Stone from Dana-Farber with his 2 #hematology fellows from Sudamerica! I was super lucky to have been able to work with these 2 gems! Dr Luis E. Aguirre, MD!

International #collaboration is key.
#Latino representation matters!!!!

Ecuador 🇪🇨 & Peru 🇵🇪 ✌🏻😎

At the NCI Center for Cancer Research Neuro-Oncology Branch, we #CareAboutRare and are dedicated to improving the lives of people with rare brain tumors. Head of the Patient Outcomes Program Dr. Terri Armstrong aims to better outcomes and quality of life for brain tumor patients. #BTAM